Catequentinib
Angiogenesis
Wenjun ChengSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Angiogenesis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Erythropoietin Human Recombinant Ajou University School of Medicine | Phase 2 | BB |
Carboplatin Wenjun Cheng | Phase 3 | BB |
Endostar Fujian Cancer Hospital | Phase 3 | B |
Olaparib Xiaoxiang Chen | Phase 2 | CCC |
(+)-VINCRISTINE Xiaoxiang Chen | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →